CA2086605A1 - Methodes de detection et de preparation des auto-anticorps anti-ige et utilisation de ces anticorps comme agents actifs dans des compositions diagnostiques et therapeutiques - Google Patents
Methodes de detection et de preparation des auto-anticorps anti-ige et utilisation de ces anticorps comme agents actifs dans des compositions diagnostiques et therapeutiquesInfo
- Publication number
- CA2086605A1 CA2086605A1 CA002086605A CA2086605A CA2086605A1 CA 2086605 A1 CA2086605 A1 CA 2086605A1 CA 002086605 A CA002086605 A CA 002086605A CA 2086605 A CA2086605 A CA 2086605A CA 2086605 A1 CA2086605 A1 CA 2086605A1
- Authority
- CA
- Canada
- Prior art keywords
- ige
- antibodies
- autoantibodies
- pos
- recombinant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 38
- 230000001225 therapeutic effect Effects 0.000 title claims abstract description 12
- 239000000203 mixture Substances 0.000 title claims description 7
- 239000013543 active substance Substances 0.000 title description 2
- 239000012634 fragment Substances 0.000 claims abstract description 21
- 208000026935 allergic disease Diseases 0.000 claims abstract description 17
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 14
- 108060003951 Immunoglobulin Proteins 0.000 claims abstract description 13
- 102000018358 immunoglobulin Human genes 0.000 claims abstract description 13
- 239000000463 material Substances 0.000 claims abstract description 13
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 13
- 238000001042 affinity chromatography Methods 0.000 claims abstract description 8
- 230000000903 blocking effect Effects 0.000 claims abstract description 8
- 238000011282 treatment Methods 0.000 claims abstract description 7
- 238000001727 in vivo Methods 0.000 claims abstract description 5
- 230000003266 anti-allergic effect Effects 0.000 claims abstract description 4
- 238000004255 ion exchange chromatography Methods 0.000 claims abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 3
- 210000001124 body fluid Anatomy 0.000 claims abstract 7
- 239000010839 body fluid Substances 0.000 claims abstract 7
- 239000007787 solid Substances 0.000 claims abstract 7
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 3
- 238000005194 fractionation Methods 0.000 claims abstract 2
- 239000013566 allergen Substances 0.000 claims description 33
- 206010020751 Hypersensitivity Diseases 0.000 claims description 16
- 230000007815 allergy Effects 0.000 claims description 14
- 238000012360 testing method Methods 0.000 claims description 10
- 238000002649 immunization Methods 0.000 claims description 9
- 230000000172 allergic effect Effects 0.000 claims description 8
- 208000010668 atopic eczema Diseases 0.000 claims description 8
- 230000003053 immunization Effects 0.000 claims description 8
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims description 7
- 238000011534 incubation Methods 0.000 claims description 7
- 239000000020 Nitrocellulose Substances 0.000 claims description 5
- 229920001220 nitrocellulos Polymers 0.000 claims description 5
- 238000000338 in vitro Methods 0.000 claims description 4
- 229960005486 vaccine Drugs 0.000 claims description 3
- 230000007935 neutral effect Effects 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 238000011158 quantitative evaluation Methods 0.000 claims description 2
- 239000000523 sample Substances 0.000 claims 6
- 238000000151 deposition Methods 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000002860 competitive effect Effects 0.000 claims 1
- 230000008021 deposition Effects 0.000 claims 1
- 239000002985 plastic film Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000003449 preventive effect Effects 0.000 claims 1
- 238000003556 assay Methods 0.000 abstract description 11
- 238000012875 competitive assay Methods 0.000 abstract description 4
- 230000015572 biosynthetic process Effects 0.000 abstract description 3
- 210000004369 blood Anatomy 0.000 abstract description 2
- 239000008280 blood Substances 0.000 abstract description 2
- 239000012530 fluid Substances 0.000 abstract 1
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 28
- 210000002966 serum Anatomy 0.000 description 16
- 229960001340 histamine Drugs 0.000 description 14
- 210000002381 plasma Anatomy 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 12
- 238000001514 detection method Methods 0.000 description 9
- 230000002052 anaphylactic effect Effects 0.000 description 8
- 210000003651 basophil Anatomy 0.000 description 8
- 230000009286 beneficial effect Effects 0.000 description 8
- 206010040914 Skin reaction Diseases 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 230000035483 skin reaction Effects 0.000 description 5
- 231100000430 skin reaction Toxicity 0.000 description 5
- 241000282560 Macaca mulatta Species 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 241000282693 Cercopithecidae Species 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000000984 immunochemical effect Effects 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 238000002616 plasmapheresis Methods 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 208000012657 Atopic disease Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 229960004784 allergens Drugs 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 229940046528 grass pollen Drugs 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- -1 sulfido leukotrienes Chemical class 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 241000182988 Assa Species 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102000009438 IgE Receptors Human genes 0.000 description 1
- 108010073816 IgE Receptors Proteins 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 206010028164 Multiple allergies Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 238000011990 functional testing Methods 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000003578 releasing effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
- C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/544—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic
- G01N33/548—Carbohydrates, e.g. dextran
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Rehabilitation Therapy (AREA)
- Rheumatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002086605A CA2086605A1 (fr) | 1991-05-10 | 1991-05-10 | Methodes de detection et de preparation des auto-anticorps anti-ige et utilisation de ces anticorps comme agents actifs dans des compositions diagnostiques et therapeutiques |
| EP91909250A EP0538266A1 (fr) | 1991-05-10 | 1991-05-10 | PROCEDE DE DETECTION ET DE PREPARATION D'AUTOANTICORPS ANTI-IgE, ET UTILISATION DE CES ANTICORPS COMME AGENTS ACTIFS DANS DES COMPOSITIONS A USAGE THERAPEUTIQUE ET DIAGNOSTIQUE |
| JP91508475A JPH05508220A (ja) | 1991-05-10 | 1991-05-10 | 抗ＩｇＥ自己抗体の検出および調製法およびこれら抗体の診断および治療組成物中での活性剤としての使用 |
| PCT/EP1991/000881 WO1992021031A1 (fr) | 1991-05-10 | 1991-05-10 | PROCEDE DE DETECTION ET DE PREPARATION D'AUTOANTICORPS ANTI-IgE, ET UTILISATION DE CES ANTICORPS COMME AGENTS ACTIFS DANS DES COMPOSITIONS A USAGE THERAPEUTIQUE ET DIAGNOSTIQUE |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002086605A CA2086605A1 (fr) | 1991-05-10 | 1991-05-10 | Methodes de detection et de preparation des auto-anticorps anti-ige et utilisation de ces anticorps comme agents actifs dans des compositions diagnostiques et therapeutiques |
| PCT/EP1991/000881 WO1992021031A1 (fr) | 1991-05-10 | 1991-05-10 | PROCEDE DE DETECTION ET DE PREPARATION D'AUTOANTICORPS ANTI-IgE, ET UTILISATION DE CES ANTICORPS COMME AGENTS ACTIFS DANS DES COMPOSITIONS A USAGE THERAPEUTIQUE ET DIAGNOSTIQUE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2086605A1 true CA2086605A1 (fr) | 1992-11-11 |
Family
ID=4150928
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002086605A Abandoned CA2086605A1 (fr) | 1991-05-10 | 1991-05-10 | Methodes de detection et de preparation des auto-anticorps anti-ige et utilisation de ces anticorps comme agents actifs dans des compositions diagnostiques et therapeutiques |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP0538266A1 (fr) |
| JP (1) | JPH05508220A (fr) |
| CA (1) | CA2086605A1 (fr) |
| WO (1) | WO1992021031A1 (fr) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113583134A (zh) * | 2020-04-30 | 2021-11-02 | 天辰生物医药(苏州)有限公司 | 分离的抗原结合蛋白及其用途 |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19505266C1 (de) * | 1995-02-16 | 1996-10-02 | Brahms Diagnostica Gmbh | Verwendung von polyklonalen humanen anti-hTg-Autoantikörpern als Reagenz für die klinische Diagnostik von Schilddrüsen-Autoimmunerkrankungen sowie Reagenziensatz für eine Bestimmung von anti-hTg-Autoantikörpern in Patientenseren |
| JP2003524602A (ja) * | 1998-09-18 | 2003-08-19 | ダイナバックス テクノロジーズ コーポレイション | ＩｇＥ関連疾患の治療方法と、その治療において使用する組成物 |
| EP1671646A3 (fr) * | 1998-09-18 | 2007-08-29 | Dynavax Technologies Corporation | Procédés de traitement de troubles associés à IgE et compositions pouvant être utilisées à cet effet. |
| US6787524B2 (en) | 2000-09-22 | 2004-09-07 | Tanox, Inc. | CpG oligonucleotides and related compounds for enhancing ADCC induced by anti-IgE antibodies |
| WO2005083385A2 (fr) * | 2004-02-26 | 2005-09-09 | Alk-Abelló A/S | Procede pour evaluer le potentiel therapeutique d'un vaccin a administration mucosale |
| EP1902320B1 (fr) | 2005-05-20 | 2010-03-10 | Genentech, Inc. | Préparation d'échantillon biologique prélevé sur un sujet souffrant de maladie auto-immune |
| RU2009140313A (ru) * | 2007-04-02 | 2011-05-10 | Эмджен Фримонт Инк. (Us) | АНТИТЕЛА ПРОТИВ IgE |
| JP5504945B2 (ja) * | 2010-02-12 | 2014-05-28 | 日東紡績株式会社 | Ｆｔｃｄとその自己抗体との複合体の免疫測定方法、それに用いるキット及びそれを用いた癌判定方法 |
-
1991
- 1991-05-10 WO PCT/EP1991/000881 patent/WO1992021031A1/fr not_active Application Discontinuation
- 1991-05-10 CA CA002086605A patent/CA2086605A1/fr not_active Abandoned
- 1991-05-10 JP JP91508475A patent/JPH05508220A/ja active Pending
- 1991-05-10 EP EP91909250A patent/EP0538266A1/fr not_active Withdrawn
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113583134A (zh) * | 2020-04-30 | 2021-11-02 | 天辰生物医药(苏州)有限公司 | 分离的抗原结合蛋白及其用途 |
| CN113583134B (zh) * | 2020-04-30 | 2024-06-04 | 天辰生物医药(苏州)有限公司 | 分离的抗原结合蛋白及其用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH05508220A (ja) | 1993-11-18 |
| WO1992021031A1 (fr) | 1992-11-26 |
| EP0538266A1 (fr) | 1993-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gearhart et al. | Heterogeneity of the BALB/c antiphosphorylcholine antibody response at the precursor cell level. | |
| US5342924A (en) | Extracellular segments of human ε immunoglobulin anchoring peptides and antibodies specific therefor | |
| JP3421970B2 (ja) | ペプチド免疫原 | |
| Ra et al. | Soluble human high-affinity receptor for IgE abrogates the IgE-mediated allergic reaction | |
| AU645783B2 (en) | Extracellular segments of human epsilon immunoglobulin anchoring peptides and antibodies specific therefor | |
| US5254671A (en) | Extracellular segments of human e immunoglobulin anchoring peptides and antibodies specific therefor | |
| CA2086605A1 (fr) | Methodes de detection et de preparation des auto-anticorps anti-ige et utilisation de ces anticorps comme agents actifs dans des compositions diagnostiques et therapeutiques | |
| JPH11513025A (ja) | アレルゲン−ｘｃｄ３２融合タンパク質 | |
| DE69530380T2 (de) | Retropeptide, antikörper dagegen und deren verwendungen in der impfung und in vitro diagnostik | |
| Huot et al. | Protection against nerve toxicity by monoclonal antibodies to the sodium channel blocker tetrodotoxin. | |
| AU705010B2 (en) | Human antibodies to t-cell receptor peptides and methods for their preparation | |
| Bruley-Rosset et al. | Polyreactive autoantibodies purified from human intravenous immunoglobulins prevent the development of experimental autoimmune diseases | |
| EP0517817B1 (fr) | Inhibiteurs d'anticorps catalytiques | |
| Mazur et al. | A common epitope on major allergens from non-biting midges (Chironomidae) | |
| Duc et al. | Monoclonal antibodies directed against T cell epitopes presented by class I MHC antigens | |
| US20030007973A1 (en) | Methods and compositions for manipulation of the immune response using anti-metallothionein antibody | |
| Thomas et al. | Heterogeneity and specificity of human anti-insulin antibodies determined by isoelectric focusing. | |
| Marchalonis et al. | An Fab-related surface component of some normal and neoplastic human and marmoset T cells: Demonstration, functional analysis and partial characterization | |
| Mourad et al. | Mapping of Lol PI allergenic epitopes by using murine monoclonal antibodies | |
| AU2002242273C1 (en) | Compositions of multimeric profilin for diagnosis and treatment of allergies | |
| Hemmens et al. | Common antigenic and allergenic determinants on codfish proteins detected with mouse monoclonal IgG and human IgE antibodies | |
| Jackson et al. | Presence of plasma cells binding autologous antibody during an immune response. | |
| Atassi et al. | Localization of the continuous allergenic sites of ragweed allergen Ra3 by a comprehensive synthetic strategy | |
| Curd et al. | Antibodies to an NH2-terminal fragment of betaS globin. I. Preparation and radioimmunoassay. | |
| AU2002242273A1 (en) | Compositions of multimeric profilin for diagnosis and treatment of allergies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |